龙沙集团（场外交易代码：LZAGY）12月空头兴趣下降28.5%——MarketBeat报道
Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 28.5% in December - MarketBeat
生命科学资讯
生物技术与制药领域的最新动态
龙沙集团期货合约 - TradingView — 追踪所有市场
Futures Contracts for Lonza Group Futures - TradingView — Track All Markets
Lonza集团（VTX:LONN）当前是否存在投资机遇？ - simplywall.st
Is There Now An Opportunity In Lonza Group AG (VTX:LONN)? - simplywall.st
Lonza集团股份（普通股）（LO3A）能否从绿色政策中获益——周度涨幅总结与技术确认提醒——宝莱坞咨询热线
Will Lonza Group AG (Common Stock) (LO3A) stock gain from green policies - Weekly Gains Summary & Technical Confirmation Alerts - Bollywood Helpline
Lonza CHI：面向新一代植物基营养保健品的有机胶囊 - nutritioninsight.com
Lonza CHI: Organic capsules for next-gen plant-based nutraceuticals - nutritioninsight.com
龙沙集团（场外交易代码：LZAGY）交易量异常激增——下一步将如何发展？——MarketBeat
Lonza Group (OTCMKTS:LZAGY) Sees Unusually-High Trading Volume - What's Next? - MarketBeat
龙沙集团、Catalent与Recipharm领跑125亿美元吸入药物合同制造市场 - pharmiweb.com
Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Mar - pharmiweb.com
龙沙集团、Catalent与Recipharm引领2025-2033年125亿美元吸入药物合同制造市场：按服务、产品、终端用途及区域分析——ResearchAndMarkets.com - AI期刊
Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Market, 2025-2033: Insights by Service, Product, End-Use and Region - ResearchAndMarkets.com - The AI Journal
Microsize通过大胆进军欧洲微粉化领域扩大全球版图 - MyChesCo
Microsize Expands Global Footprint With Bold Move Into European Micronization - MyChesCo
龙沙集团增长倚重生物制剂，但风险犹存——Finimize
Lonza’s Growth Hinges On Biologics, But Risks Remain - Finimize
隆扎集团普通股（LO3A）在通胀压力下的表现分析——2025年7月最后一周及风险管理投资信号
How Lonza Group AG (Common Stock) (LO3A) stock behaves under inflation pressure - July 2025 Final Week & Risk Managed Investment Signals - Newser
Lonza集团AG（普通股）（LO31）股价交易波动剧烈——2025年7月新闻驱动因素与每日技术预测报告——Newser
How Lonza Group AG (Common Stock) (LO31) stock trades in high volatility - July 2025 News Drivers & Daily Technical Forecast Reports - Newser
朗盛集团（普通股）LO3A股票MACD趋势信号解读——交易量总结与短期高回报策略——新瑟报
What MACD trends signal for Lonza Group AG (Common Stock) (LO3A) stock - Trade Volume Summary & Short-Term High Return Ideas - Newser
摩根士丹利维持对龙沙集团(LONN)的买入评级 - 《环球邮报》
Morgan Stanley Keeps Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
生物制剂CDMO市场趋势及至2033年投资预测：龙沙集团与Cata公司特性分析 - PharmiWeb.com
Biologics CDMO Market Trends and Investment Forecast to 2033: Features Analysis of Lonza Group, Cata - PharmiWeb.com
龙沙集团(OTCMKTS:LZAGY)交易量强劲攀升——买入时机已至？- MarketBeat
Lonza Group (OTCMKTS:LZAGY) Sees Strong Trading Volume - Time to Buy? - MarketBeat
中东细胞与基因疗法CDMO市场预测至2033年，重点企业战略剖析 - PharmiWeb.com
Middle East Cell and Gene Therapy CDMO Market Forecast to 2033 Featuring Strategic Profiles of Key P - PharmiWeb.com
Lonza集团（普通股）LO31股票将发布积极指引——2025年价格目标与风险控制每日计划——新报
Will Lonza Group AG (Common Stock) (LO31) stock issue positive guidance - 2025 Price Targets & Risk Controlled Daily Plans - Newser
Lonza集团AG（普通股）(LO3A)股票的MACD趋势信号解读——Newser
What MACD trends signal for Lonza Group AG (Common Stock) (LO3A) stock - Newser
微尺寸公司携手Schedio收购龙沙瑞士微粉化工厂——Fierce Pharma报道
Microsize, Schedio link to buy Lonza’s Swiss micronization plant - Fierce Pharma